Dyne Therapeutics Announces Upsized Public Offering

An announcement from Dyne Therapeutics ( (DYN) ) is now available.

On December 9, 2025, Dyne Therapeutics announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at $18.44 per share, expected to raise $350 million before expenses. The offering, managed by Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities, is anticipated to close around December 11, 2025, with an option for underwriters to purchase additional shares. The proceeds, combined with existing resources, are expected to fund Dyne’s operations into the first quarter of 2028, enhancing its financial runway and supporting its strategic initiatives in the neuromuscular disease sector.

The most recent analyst rating on (DYN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Dyne Therapeutics stock, see the DYN Stock Forecast page.

Spark’s Take on DYN Stock

According to Spark, TipRanks’ AI Analyst, DYN is a Neutral.

Dyne Therapeutics’ stock score reflects its current financial health as a pre-revenue biotech, burdened by losses but supported by a strong balance sheet and recent strategic leadership changes. Technical indicators suggest bearish trends, yet the potential for future breakthroughs could alter its trajectory.

To see Spark’s full report on DYN stock, click here.

More about Dyne Therapeutics

Dyne Therapeutics is a clinical-stage company focused on delivering functional improvement for individuals with genetically driven neuromuscular diseases. The company is developing therapeutics targeting muscle and the central nervous system to address the root causes of diseases like myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease.

Average Trading Volume: 2,803,681

Technical Sentiment Signal: Buy

Current Market Cap: $3.17B

For a thorough assessment of DYN stock, go to TipRanks’ Stock Analysis page.